CAJ | 학술논문

目的观察重组人白细胞介素-11(rhIL-11)对急性白血病(AL)化疗后血小板(Plt)减少的疗效.方法对42例AL(治疗组)化疗后Pit＜20×109/L的患者皮下注射rhIL-111.5 mg/d,用至Plt≥40×109/L停药;对其中17例初诊急性髓系白血病(AML)完成2个疗程化疗后统计疗效,并以35例未加用rhIL-11的AL患者和其中15例初诊AML(对照组)完成2个疗程化疗患者作对照.结果治疗组Plt升到≥40×109/L所需时间平均为(9.8±2.7)d,短于对照组(14.6±4.8)d(P＜0.05);治疗组在第2个疗程化疗后Ph＜15×109/L的患者有3例(17.6%),明显少于对照组10例(66.7%)(P＜0.05);第2个疗程化疗前Plt水平和化疗后Plt最低平均水平,治疗组为(173.7±81.2)×109/L和(23,5±18.3)X 109/L高于对照组(99.6±74.5)×109/L和(10.2±9.8)×109/L(P＜0.05);治疗组和对照组的完全缓解(CR)率分别是70.6%和73.3%,有效(CR+PR)率分别是82.4%和86.7%,二组比较差异无统计学意义(P＞0.05).结论 rhIL-11可安全有效地促进AL化疗后Plt恢复,而且疗效持久.
목적 관찰중조인백세포개소-11(rhIL-11)대급성백혈병(AL)화료후혈소판(Plt)감소적료효.방법 대42례AL(치료조)화료후Pit＜20×109/L적환자피하주사rhIL-111.5 mg/d,용지Plt≥40×109/L정약;대기중17례초진급성수계백혈병(AML)완성2개료정화료후통계료효,병이35례미가용rhIL-11적AL환자화기중15례초진AML(대조조)완성2개료정화료환자작대조.결과 치료조Plt승도≥40×109/L소수시간평균위(9.8±2.7)d,단우대조조(14.6±4.8)d(P＜0.05);치료조재제2개료정화료후Ph＜15×109/L적환자유3례(17.6%),명현소우대조조10례(66.7%)(P＜0.05);제2개료정화료전Plt수평화화료후Plt최저평균수평,치료조위(173.7±81.2)×109/L화(23,5±18.3)X 109/L고우대조조(99.6±74.5)×109/L화(10.2±9.8)×109/L(P＜0.05);치료조화대조조적완전완해(CR)솔분별시70.6%화73.3%,유효(CR+PR)솔분별시82.4%화86.7%,이조비교차이무통계학의의(P＞0.05).결론 rhIL-11가안전유효지촉진AL화료후Plt회복,이차료효지구.
Objective To investigate the treatment of recombinant human interleukin-11(rhIL-11)to chemotherapy-induced thrombocytopenia in acute leukemia(AL).Methods 42 AL patients whose platelet count dropped below 20×109/L after chemotherapy received rhIL-11 by 1.5 mg daily until the platelet count was increased above 40×109/L.The efficiency of chemotherapy to 17 newly diagnosed acute myelocytic leukemia(AML)patients was evaluated after receiving two periods of chemotherapy.35 AL patients and 15 newly diagnosed AML patients were used as controls.Results The mean time of platelet count increasing from 20×109/L to above 40×109/L Was shorter in treating group (9.8±2.7)d than in control group(14.6±4.8)d .The number of patients whose platelet＜15×109/L was less in treating group than in control group after second chemotherapy,and the minimum mean count of platelet Was higher in treating group(23.5±18.3)×109/L than that in control group(10.2±9.8)×109/L .CR and CR+PR rate were not different between treating group and control group. Conclusion rhlL-11 can safely and effectively promote chemotherapy-induced platelet recovery in patients of acute leukemia with persistent affection.